Blue Paper: COVID-19 Quick-Test

4 Pages Posted: 17 Mar 2020 Last revised: 13 Apr 2020

See all articles by Mikael Franzén

Mikael Franzén

Galevant Institute; Alten Group - Alten Sweden

Date Written: March 9, 2020

Abstract

In the light of the current global situation, a new inexpensive rapid test for COVID-19 has been conceptually developed and the details are outlined in this document. Given the lack of approved vaccines and anti-viral drugs, the importance of quick diagnoses cannot be understated.

Research suggest that antigen material should be readily available in serological samples from the onset until the end of infection. Hence, a direct antigen rapid test, such as the one to be presented here, has the advantage of not being dependent on immune response and the availability of specific immunoglobulin antibodies. Diagnosis should therefore be possible from the first day of symptoms. This is very significant and means that acute diagnosis is theoretically possible.

Note: Funding: None.

Declaration of Interest: The authors "declare no competing or conflict of interest."

Keywords: Antigen, Analytical Chemistry, Bioanalytical, Biochemistry, Chemistry, COVID-19, COVID-19 Quick Test, Covid-19 Rapid Test, Diagnostics, Diagnostic testing, Enzyme Linked Immunosorbent Assay Immunoassay, Immunochemistry, Lateral Flow Imunoassay, LFIA, POC, Point-of-Care, Quick Test, Virology, Virus

Suggested Citation

Franzén, Mikael, Blue Paper: COVID-19 Quick-Test (March 9, 2020). Available at SSRN: https://ssrn.com/abstract=3551647 or http://dx.doi.org/10.2139/ssrn.3551647

Mikael Franzén (Contact Author)

Galevant Institute ( email )

Sjömannen
Jungfrusund
Ekerö, 178 51
Sweden

HOME PAGE: http://www.galevant.org

Alten Group - Alten Sweden ( email )

Knarrarnäsgatan 7
Kista, 164 40
Sweden

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
455
Abstract Views
2,734
Rank
157,424
PlumX Metrics